Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2025)

Lyell Immunopharma's Total Current Liabilities history spans 6 years, with the latest figure at $31.9 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 4.88% year-over-year to $31.9 million; the TTM value through Sep 2025 reached $31.9 million, down 4.88%, while the annual FY2024 figure was $53.8 million, 55.82% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $31.9 million at Lyell Immunopharma, down from $36.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $63.7 million in Q2 2021 and bottomed at $30.8 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $37.0 million (2022), against an average of $41.4 million.
  • The largest annual shift saw Total Current Liabilities tumbled 31.62% in 2023 before it surged 55.82% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $46.7 million in 2021, then decreased by 20.78% to $37.0 million in 2022, then decreased by 6.78% to $34.5 million in 2023, then surged by 55.82% to $53.8 million in 2024, then crashed by 40.73% to $31.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Total Current Liabilities are $31.9 million (Q3 2025), $36.9 million (Q2 2025), and $41.3 million (Q1 2025).